Product
SOC
Aliases
bDMARD or csDMARD, SOC (Standard of care)
6 clinical trials
9 indications
Indication
Stage III Pancreatic CancerIndication
Rheumatoid ArthritisIndication
Critical Limb IschemiaIndication
Thromboangiitis obliteransIndication
Thromboangiitis ObliteransIndication
Atherosclerosis ObliteransIndication
Antiphospholipid SyndromeIndication
HIV InfectionsIndication
Small Cell Lung CancerClinical trial
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 2a Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Burfiralimab(hzVSF-v13) Added to Disease-modifying Antirheumatic Drugs in Participants With Moderate to Severe RAStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD)Status: Completed, Estimated PCD: 2022-05-19
Clinical trial
A Single Center, Randomized Controlled, Open Trial Exploring the Regulatory Effect of Telitacicept on Antibody Titers in Primary Antiphospholipid Syndrome Patients Carrying High-risk Antiphospholipid Antibody ProfilesStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomised Non-inferiority Trial With Nested PK to Assess DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years OldStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
Evaluation of Safety and Efficacy of Serplulimab Plus Chemotherapy in Patients With Histological Transformation From EGFR-mutated NSCLC to SCLC After Treatment: a Single-arm, Multicenter, Open-label Phase II StudyStatus: Recruiting, Estimated PCD: 2025-06-30